Compare FTAI Aviation Ltd (FTAI) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs GSK plc — how do they compare? FTAI Aviation Ltd trades at $170.06 (market cap $17.57B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 5.2× FTAI Aviation Ltd's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and GSK plc for 93 Days on average.
| FTAI | GSK | |
|---|---|---|
Market Cap | $17.57B | $91.88B |
Volume | 1,905,014 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $310.04 | $61.18 |
52-Week Low | $152.80 | $43.24 |
Typical Hold Time | 23 Days | 93 Days |
Enterprise Value | $20.69B | $111.88B |
Dividend Yield | 1.17% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $169.47, down 3.07% today, with a bearish technical signal from moving averages. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS expectations. Recent developments include a $500M share buyback program and a strategic acquisition of 27 Boeing aircraft, signaling growth focus. Analyst consensus remains unanimously bullish with a $321.25 price target, highlighting institutional confidence despite near-term earnings volatility.
The outlook for FTAI is positive based on robust analyst support and strategic expansions, but risks include consecutive EPS misses and a high P/E ratio of 37.35. Investors face volatility from operational cash flow challenges and competitive pressures in the aviation sector, though the buyback and new partnerships provide catalysts for recovery.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
